Gilead taps Durham gene editing firm for $445M deal
September 14, 2018 at 07:00 AM EDT
California biotech Gilead Sciences (Nasdaq: GILD) has teamed up with a Durham-based Precision BioSciences to develop therapies targeting hepatitis B – a deal that could be worth $445 million.